Retatrutide vs Dulaglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: LY3437943, Triple G
A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
Also: Trulicity
An FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.
Key Comparison Insights
- Dulaglutide is FDA approved, while Retatrutide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Dulaglutide has stronger research evidence (FDA Approved) compared to Retatrutide (Human Trials).
Detailed Comparison
| Attribute | Retatrutide | Dulaglutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Retatrutide activates three receptors: GLP-1 for appetite suppression and glucose control, GIP for enhanced insulin response and metabolic effects, and glucagon for increased energy expenditure and fat oxidation. The triple mechanism provides synergistic effects. | Dulaglutide consists of two GLP-1 analogs linked to a modified human IgG4 Fc fragment. This structure extends half-life to about 5 days, allowing weekly dosing. Works through standard GLP-1 receptor activation. |
| Common Dosing | 4-12 mg weekly Once weekly, same day each week | 1.5-4.5 mg weekly Once weekly |
| Administration | Subcutaneous injection weekly | Subcutaneous injection weekly |
| Typical Duration | Long-term use expected | Long-term / chronic use |
| Best Time to Take | Morning, same day each week | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase 3 TRIUMPH-4 trial (Dec 2025) showed 28.7% weight loss at 68 weeks, with average loss of 71 lbs. Also showed significant osteoarthritis pain relief, reduced cardiovascular risk markers, and 14 mmHg blood pressure reduction. Seven more Phase 3 readouts expected in 2026. NDA submission expected late 2025/early 2026. | AWARD program showed significant A1C reduction and weight loss. REWIND trial demonstrated cardiovascular benefits in broader diabetic population. Generally shows 3-5% weight loss in trials. |
Frequently Asked Questions: Retatrutide vs Dulaglutide
What is the difference between Retatrutide and Dulaglutide?
Retatrutide is a weight loss peptide that a triple agonist targeting glp-1, gip, and glucagon receptors. phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. expected fda approval late 2026 to early 2027. Dulaglutide is a weight loss peptide that an fda-approved weekly glp-1 receptor agonist for type 2 diabetes. fused to an fc antibody fragment for extended duration of action. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Retatrutide or Dulaglutide?
Neither is universally "better" - the choice depends on your specific goals. Retatrutide is typically used for weight loss purposes, while Dulaglutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Retatrutide and Dulaglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Retatrutide and Dulaglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Retatrutide and Dulaglutide is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.